查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591802

肝炎檢測解決方案/診斷市場：按疾病類型、技術和最終用戶分類 - 全球預測 2025-2030 年

Hepatitis Test Solution/Diagnosis Market by Disease Type, Technology, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

肝炎檢測解決方案/診斷市場2023年估值為35.3億美元，預計到2024年將達到37.1億美元，複合年成長率為5.48%，到2030年將達到51.3億美元。

在肝炎檢測解決方案和診斷領域，市場範圍包括旨在檢測和管理不同類型肝炎感染（甲型、乙型、丙型、丁型、戊型）的各種產品和技術。這些解決方案的需求很大程度上是由於藥物使用增加、不安全輸血和無保護性行為等因素導致肝炎發病率上升。應用範圍涵蓋醫院、診斷實驗室和研究組織，最終用戶包括醫療保健提供者、公共衛生組織和個別患者。

主要市場統計
基準年[2023] 35.3億美元
預測年份 [2024] 37.1億美元
預測年份 [2030] 51.3億美元
複合年成長率（%） 5.48%

由於診斷測試技術的進步，包括採用 PCR、免疫測量和就地檢驗，提高了診斷的準確性和速度，該市場正在經歷顯著成長。特別是在新興市場，政府提高意識和篩檢的努力正在對成長產生重大影響。此外，不斷成長的醫療保健支出和不斷成長的早期檢測需求正在為市場進入者創造潛在機會。然而，市場面臨一些限制，例如與先進測試解決方案相關的高成本、意識有限（尤其是在新興市場）以及嚴格的法規結構抑制了市場的快速滲透。

潛在的創新領域包括開發低成本快速檢測套組、攜帶式診斷設備以及改進的基於人工智慧的資料分析，以提供更好的預測見解和患者管理平台。這些進步有可能大大促進資源有限環境中的廣泛獲取和實施。市場競爭激烈，主要企業不斷進步並結盟，推出更強大的診斷工具。企業應專注於加強研發能力，與技術創新者形成策略聯盟，打造差異化產品。我們還可以透過肝炎預防和檢測的宣導活動來開拓開拓的市場，從而擴大我們的市場覆蓋範圍並推動成長。

市場動態：揭示快速發展的肝炎檢測解決方案/診斷市場的關鍵市場洞察

供需的動態交互作用正在改變肝炎檢測解決方案/診斷市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球肝炎盛行率上升
    • 疾病早期發現與診斷的必要性
    • 提高政府和非營利組織對肝炎的認知
  • 市場限制因素
    • 檢測和診斷肝炎的費用高昂
  • 市場機會
    • 病毒性肝炎檢測與診斷的進展
    • 就地檢驗選項簡介
  • 市場挑戰
    • 與不準確的測試結果相關的擔憂

波特五力：引領肝炎檢測解決方案/診斷市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解肝炎檢測解決方案/診斷市場的外部影響

外部宏觀環境因素在塑造肝炎檢測解決方案/診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解肝炎檢測解決方案/診斷市場的競爭狀況

肝炎檢測解決方案/診斷市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣肝炎檢測解決方案/診斷市場供應商的績效評估

FPNV 定位矩陣是評估肝炎檢測解決方案/診斷市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，描繪肝炎檢測解決方案/診斷市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對肝炎檢測解決方案/診斷市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地的肝炎發生率正在上升
      • 疾病早期發現與診斷的必要性
      • 政府和非營利組織意識提升
    • 抑制因素
      • 檢測和診斷肝炎的費用高昂
    • 機會
      • 病毒性肝炎檢測與診斷的進展
      • 就地檢驗選項簡介
    • 任務
      • 與不準確的測試結果相關的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章肝炎檢測解決方案/診斷市場：依疾病類型

  • 甲型肝炎
  • B型肝炎
  • C型肝炎

第7章肝炎檢測解決方案/診斷市場：依技術分類

  • 酵素免疫分析法
  • 恒溫核酸增幅技術
  • 聚合酵素鏈鎖反應
  • 快速診斷測試

第 8 章 肝炎檢測解決方案/診斷市場：依最終使用者分類

  • 血庫
  • 診斷實驗室
  • 醫院

第9章北美和南美的肝炎檢測解決方案/診斷市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區肝炎檢測解決方案/診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的肝炎檢測解決方案/診斷市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 賽諾菲宣佈在英國推出 AVAXIM Junior，作為 12 個月至 15 歲兒童甲型肝炎病毒感染的主動免疫治療
    • UnitAid 投資 3,100 萬美元減少傷害工作，以預防注射毒品者和高風險族群中的C型肝炎
    • 衛生署與當地實驗室合作擴大可治癒丙型肝炎的檢測
    • 羅氏推出雙抗體/抗原丙型C型肝炎病毒診斷測試
    • 雅培推出檢測B型肝炎病毒的解決方案
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Avantor Inc.
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories Inc.
  • bioMerieux SA
  • Cepheid
  • Creative Diagnostics
  • DiaSorin SpA
  • Epitope Diagnostics, Inc.
  • Everlywell, Inc.
  • F. Hoffmann-La Roche AG
  • FUJIREBIO Inc.
  • GenMark Diagnostics, Inc.
  • Grifols SA
  • Hologic, Inc.
  • Laboratory Corporation of America Holdings
  • MedMira Inc.
  • Merck & Co., Inc
  • Meridian Bioscience, Inc.
  • OraSure Technologies, Inc.
  • Ortho Clinical Diagnostics
  • Prometheus Laboratories
  • QIAGEN GmbH
  • Quest Diagnostics Incorporated
  • Randox Laboratories
  • Sanofi SA
  • Siemens AG
  • Thermo Fisher Scientific Inc.
  • Vela Diagnostics
  • Werfen, SA
Product Code: MRR-43127F727883

The Hepatitis Test Solution/Diagnosis Market was valued at USD 3.53 billion in 2023, expected to reach USD 3.71 billion in 2024, and is projected to grow at a CAGR of 5.48%, to USD 5.13 billion by 2030.

In the arena of Hepatitis Test Solutions and Diagnostics, the market scope encompasses a range of products and technologies designed to detect and manage different types of hepatitis infections (A, B, C, D, E). The necessity of these solutions is largely propelled by rising incidences of hepatitis due to factors like increased drug use, unsafe blood transfusions, and unprotected sex. Their application spans across hospitals, diagnostic laboratories, and research institutes, with end-users including healthcare providers, public health organizations, and individual patients.

KEY MARKET STATISTICS
Base Year [2023] USD 3.53 billion
Estimated Year [2024] USD 3.71 billion
Forecast Year [2030] USD 5.13 billion
CAGR (%) 5.48%

The market is witnessing substantial growth due to technological advancements in diagnostic testing, such as the adoption of PCR, Immunoassays, and point-of-care testing, which enhance the accuracy and speed of diagnosis. Government initiatives to increase awareness and screening, especially in emerging markets, are significantly influencing growth. Additionally, increasing healthcare expenditures and the rising demand for early detection are creating potential opportunities for market players. However, the market faces limitations such as high costs associated with advanced testing solutions, limited awareness, especially in developing regions, and stringent regulatory frameworks that can impede rapid market penetration.

Potential areas of innovation include the development of low-cost, rapid testing kits, portable diagnostic devices, and improvement in AI-based data analytics to provide better predictive insights and patient management platforms. These advances could greatly facilitate wider access and implementation in resource-limited settings. The nature of the market is highly competitive with continuous advancements and collaborations among key players to introduce more robust diagnostic tools. Companies should focus on strengthening their R&D capabilities and forming strategic alliances with technological innovators to create differentiated products. Exploring untapped markets through educational initiatives about hepatitis prevention and testing can also increase market reach and facilitate growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hepatitis Test Solution/Diagnosis Market

The Hepatitis Test Solution/Diagnosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of hepatitis worldwide
    • Need for earlier detection and diagnosis of diseases
    • Increasing awareness about hepatitis by government and non-profit organizations
  • Market Restraints
    • High cost associated with tests and diagnosis of hepatitis
  • Market Opportunities
    • Advances in viral hepatitis testing and diagnosis
    • Introduction of point-of-care testing options
  • Market Challenges
    • Concerns associated with inaccurate test results

Porter's Five Forces: A Strategic Tool for Navigating the Hepatitis Test Solution/Diagnosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hepatitis Test Solution/Diagnosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hepatitis Test Solution/Diagnosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hepatitis Test Solution/Diagnosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hepatitis Test Solution/Diagnosis Market

A detailed market share analysis in the Hepatitis Test Solution/Diagnosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hepatitis Test Solution/Diagnosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hepatitis Test Solution/Diagnosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hepatitis Test Solution/Diagnosis Market

A strategic analysis of the Hepatitis Test Solution/Diagnosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hepatitis Test Solution/Diagnosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Avantor Inc., Beckman Coulter, Inc., Bio-Rad Laboratories Inc., bioMerieux SA, Cepheid, Creative Diagnostics, DiaSorin S.p.A., Epitope Diagnostics, Inc., Everlywell, Inc., F. Hoffmann-La Roche AG, FUJIREBIO Inc., GenMark Diagnostics, Inc., Grifols S.A., Hologic, Inc., Laboratory Corporation of America Holdings, MedMira Inc., Merck & Co., Inc, Meridian Bioscience, Inc., OraSure Technologies, Inc., Ortho Clinical Diagnostics, Prometheus Laboratories, QIAGEN GmbH, Quest Diagnostics Incorporated, Randox Laboratories, Sanofi S.A., Siemens AG, Thermo Fisher Scientific Inc., Vela Diagnostics, and Werfen, S.A..

Market Segmentation & Coverage

This research report categorizes the Hepatitis Test Solution/Diagnosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Hepatitis A, Hepatitis B, and Hepatitis C.
  • Based on Technology, market is studied across Enzyme-Linked Immunosorbent Assay, Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, and Rapid Diagnostic Tests.
  • Based on End-User, market is studied across Blood Banks, Diagnostic Laboratories, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of hepatitis worldwide
      • 5.1.1.2. Need for earlier detection and diagnosis of diseases
      • 5.1.1.3. Increasing awareness about hepatitis by government and non-profit organizations
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with tests and diagnosis of hepatitis
    • 5.1.3. Opportunities
      • 5.1.3.1. Advances in viral hepatitis testing and diagnosis
      • 5.1.3.2. Introduction of point-of-care testing options
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with inaccurate test results
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hepatitis Test Solution/Diagnosis Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Hepatitis A
  • 6.3. Hepatitis B
  • 6.4. Hepatitis C

7. Hepatitis Test Solution/Diagnosis Market, by Technology

  • 7.1. Introduction
  • 7.2. Enzyme-Linked Immunosorbent Assay
  • 7.3. Isothermal Nucleic Acid Amplification Technology
  • 7.4. Polymerase Chain Reaction
  • 7.5. Rapid Diagnostic Tests

8. Hepatitis Test Solution/Diagnosis Market, by End-User

  • 8.1. Introduction
  • 8.2. Blood Banks
  • 8.3. Diagnostic Laboratories
  • 8.4. Hospitals

9. Americas Hepatitis Test Solution/Diagnosis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Hepatitis Test Solution/Diagnosis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Hepatitis Test Solution/Diagnosis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Sanofi Announces Launch of AVAXIM Junior in the UK for Active Immunization Against Infection Caused by the Hepatitis A Virus in Children Aged 12 Months to 15 Years
    • 12.3.2. Unitaid Makes USD 31 Million Investment in Harm Reduction Efforts to Prevent Hepatitis C Among People who Inject Drugs and Others at High Risk
    • 12.3.3. DOH Partners with Local Laboratories to Expand Testing for Curable Hepatitis C
    • 12.3.4. Roche Launches Dual Antibody, Antigen Hepatitis C Virus Diagnostic Test
    • 12.3.5. Abbott launches solution to detect Hepatitis B virus
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Avantor Inc.
  • 4. Beckman Coulter, Inc.
  • 5. Bio-Rad Laboratories Inc.
  • 6. bioMerieux SA
  • 7. Cepheid
  • 8. Creative Diagnostics
  • 9. DiaSorin S.p.A.
  • 10. Epitope Diagnostics, Inc.
  • 11. Everlywell, Inc.
  • 12. F. Hoffmann-La Roche AG
  • 13. FUJIREBIO Inc.
  • 14. GenMark Diagnostics, Inc.
  • 15. Grifols S.A.
  • 16. Hologic, Inc.
  • 17. Laboratory Corporation of America Holdings
  • 18. MedMira Inc.
  • 19. Merck & Co., Inc
  • 20. Meridian Bioscience, Inc.
  • 21. OraSure Technologies, Inc.
  • 22. Ortho Clinical Diagnostics
  • 23. Prometheus Laboratories
  • 24. QIAGEN GmbH
  • 25. Quest Diagnostics Incorporated
  • 26. Randox Laboratories
  • 27. Sanofi S.A.
  • 28. Siemens AG
  • 29. Thermo Fisher Scientific Inc.
  • 30. Vela Diagnostics
  • 31. Werfen, S.A.

LIST OF FIGURES

  • FIGURE 1. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET RESEARCH PROCESS
  • FIGURE 2. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2023